Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
TORONTO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 ("PDC") and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 ("COVID-19") vaccine.
多倫多，2022年2月7日(環球通訊社)--Theralase®Technologies Inc.(“Theralase®“或”公司") (TSXV：TLT) (OTCQB：TLTFF)，一家專注於光激活光動力化合物研發的臨牀期製藥公司1 ("PDC)及其相關藥物配方，旨在安全有效地殺滅各種癌症、細菌和病毒，已經為加拿大製造的SARS-CoV-2的開發提供了概念證明(新冠肺炎“)疫苗。
In August 2020, Theralase® reported that it had executed a Sponsored Research Agreement ("SRA") with the University of Manitoba ("UM") medical microbiology department to commence research and development of a Canadian-made vaccine, utilizing Theralase®'s patented and proprietary PDC, TLD-1433.
2020年8月，Theralase®報告稱，它已簽署了一項贊助研究協議(“SRA“)與馬尼託巴大學合作(”恩“)醫療微生物學部門利用Theralase®的專利和專有PDC TLD-1433，開始研發加拿大製造的疫苗。
In November 2020, Theralase® reported that, UM was able to demonstrate that TLD-1433 was effective in the rapid destruction of various viruses, including: H1N1 Influenza, Zika and a Biological Safety Level ("BSL")-2 coronavirus at low nanomolar ("nM") concentrations.
2020年11月，Theralase®報告説，UM能夠證明TLD-1433在快速銷燬各種病毒方面是有效的，包括：H1N1流感、寨卡病毒和生物安全級別(BSL“)-2低納米分子冠狀病毒(”尼姆“)濃度。
All these enveloped viruses are similar in structure to SARS-CoV-2 virus (BSL-3), which is responsible for COVID-19. These initial results strongly suggested that Theralase®'s PDC technology may be used to develop an inactivated virus vaccine2 that may be effective against COVID-19 and hence warranted further preclinical evaluation.
所有這些被包裹的病毒在結構上都與導致新冠肺炎的SARS-CoV-2病毒(BSL-3)相似。這些初步結果強烈表明Theralase®的PDC技術可用於開發滅活病毒疫苗2這可能對新冠肺炎有效，因此需要進一步的臨牀前評估。
Further research by UM also identified that the spike protein responsible for the transmission of a coronavirus into a host cell, remained intact after light-activated TLD-1433 inactivation, suggesting that the vaccine developed by this technology could potentially stimulate a protective antibody immune response in a mammalian host.
UM的進一步研究還發現，負責將冠狀病毒傳播到宿主細胞的尖峯蛋白在光激活TLD-1433滅活後保持完好，這表明通過這項技術開發的疫苗可能會在哺乳動物宿主中激發保護性抗體免疫反應。
In April 2021, Theralase® reported that it had executed a Collaborative Research Agreement ("CRA") with the Public Health Agency of Canada's ("PHAC") National Microbiology Laboratory to further expand upon the research and development achieved at UM, by researching and developing a Canadian-based COVID-19 vaccine.
2021年4月，Theralase®報告説，它已經簽署了一項合作研究協議(“CRA“)與加拿大公共衞生局(”PHAC“)國家微生物實驗室在密歇根州州立大學取得的研究和開發成果的基礎上，通過研究和開發一種加拿大的新冠肺炎疫苗，進一步擴大研究和開發範圍。
Under the terms of the agreement, Theralase® and PHAC are collaborating on the research, development and optimization of a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with Theralase®'s light-activated PDC, TLD-1433.
根據協議條款，Theralase®和PHAC正在合作研究、開發和優化新冠肺炎疫苗，方法是使用Theralase®的光活化PDC TLD-1433來滅活SARS-CoV-2病毒。
Theralase® is pleased to be able to report today that PHAC has demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study. Further research is required to confirm these findings.
Theralase®今天很高興地報告，PHAC在體外研究中證明，與對照相比，光激活TLD-1433在快速滅活SARS-CoV-2病毒方面的有效性高達99.99%。需要進一步的研究來證實這些發現。
These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.
這些結果現在已經為下一階段的CRA奠定了基礎，該階段正在評估Theralase®新冠肺炎疫苗在防止動物接觸病毒時感染新冠肺炎的能力。
Darwyn Kobasa, Ph.D., Head, High Containment Respiratory Virus Group, Special Pathogens, PHAC, stated, "My team's initial results indicate that, when activated by light, TLD-1433 is very effective in inactivating the COVID-19 virus at low concentrations, thus demonstrating proof-of-concept in the development of a Canadian-made COVID-19 vaccine."
特別病原體協會高遏制呼吸道病毒組組長Darwyn Kobasa博士説：“我的團隊的初步結果表明，當被光線激活時，在低濃度下，TLD1433在滅活新冠肺炎病毒方面非常有效，從而證明瞭加拿大製造的新冠肺炎疫苗的開發是可行的。”
Kevin Coombs, Ph.D., Professor, Department of Medical Microbiology at UM, stated, "The work conducted at my lab and the work conducted by PHAC's National Microbiology Laboratory, has demonstrated that a large range of enveloped viruses can be successfully inactivated by light-activated TLD-1433 at low concentrations. I am delighted that Theralase®'s and my initial preclinical research has proven to be effective in COVID-19."
密歇根大學醫學微生物學系教授、博士凱文·庫姆斯説：“我的實驗室和PHAC國家微生物實驗室進行的工作已經證明，在低濃度下，光激活的TLD1433可以成功滅活大量被包裹的病毒。我很高興Theralase®和我的初步臨牀前研究已被證明在新冠肺炎有效。”
Dr. Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated, "The latest preliminary results by Dr. Kobasa and Dr. Coombs, demonstrate that the Theralase® vaccine may potentially be effective as a Canadian-made wholly-inactivated vaccine to prevent individuals from contracting COVID-19 in the future and warrant further research to confirm the findings. The research also demonstrates that the Theralase® platform is extremely versatile, with an ability to be applicable to a wide range of enveloped viruses. This would allow the Company to tailor the vaccine to be potentially effective against contracting various viruses (existing and/or new) and their associated variants. Based on this encouraging data, the Company intends to move forward in the research, development and commercialization of the Theralase® COVID-19 vaccine, subject to the required regulatory approval."
Theralase®臨時首席執行官兼首席科學官Arkady Mandel博士(醫學博士、博士和博士)表示：“Kobasa博士和Coombs博士的最新初步結果表明，Theralase®疫苗有可能作為加拿大製造的全滅活疫苗有效，以防止個人在未來感染新冠肺炎，並需要進一步的研究來證實這些發現。研究還表明，Theralase®平臺具有極強的通用性，能夠適用於多種包膜病毒。這將允許該公司定製疫苗，使其對感染各種病毒(現有的和/或新的)及其相關變種具有潛在的有效性。基於這些令人鼓舞的數據，該公司打算在獲得必要的監管部門批准的情況下，推進Theralase®新冠肺炎疫苗的研究、開發和商業化。“
| 1 | PDCs are Light sensitive compounds that when activated by light at a particular wavelength can produce reactive oxygen species that can cause inactivation of cells or viruses through oxidative stress. |
| 2 | The Company does not claim or profess that they have the ability to treat, cure or prevent the contraction of the COVID-19 coronavirus. |
| 1 | PDCs是一種光敏化合物，當被特定波長的光激活時，可以產生活性氧物種，從而通過氧化應激導致細胞或病毒失活。 |
| 2 | 該公司並不聲稱或聲稱他們有能力治療、治癒或防止新冠肺炎冠狀病毒的感染。 |
About TLD-1433
關於TLD-1433
TLD-1433 is a patented PDC with over 10 years of published peer reviewed preclinical research and is currently under investigation in a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study for Bacillus Calmette-Guérin ("BCG")-Unresponsive patients at 5 Canadian Clinical Study Sites ("CSS") and 7 US-based CSS.
TLD-1433是一種獲得專利的PDC，經過10多年的同行評審臨牀前研究，目前正在進行II期非肌肉浸潤性膀胱癌的研究(“NMIBC“)卡介苗的臨牀研究卡介苗“)-加拿大5個臨牀研究地點的無反應患者(”CSS“)和7個總部位於美國的CSS。
About Theralase® Technologies Inc.:
關於Theralase®Technologies Inc.：
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses.
Theralase®是一家臨牀階段的製藥公司，致力於研究和開發光激活的光動力化合物及其相關藥物配方，旨在安全有效地殺死各種癌症、細菌和病毒。
Additional information is available at and
欲瞭解更多信息，請訪問和
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Forward Looking Statements
前瞻性陳述
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations and a COVID-19 vaccine. Forward-looking statements may be identified by the use of the words "may", "should", "will", "anticipates", "believes", "plans", "expects", and similar expressions including statements related to the current expectations of Company's management for future research, development and commercialization of the Company's COVID vaccine, including preclinical research, clinical studies and regulatory approvals.
本新聞稿包含適用於加拿大證券法的“前瞻性陳述”。這些陳述包括但不限於有關該公司提出的有關光動力化合物及其藥物配方和新冠肺炎疫苗的開發計劃的陳述。前瞻性陳述可以通過使用以下詞語來識別：“可能", "應該", "將要", "預計", "vbl.相信，相信", "平面圖", "期望以及類似的表述，包括與公司管理層目前對公司COVID疫苗未來研究、開發和商業化的期望有關的陳述，包括臨牀前研究、臨牀研究和監管批准。
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to: adequately fund, and secure the requisite regulatory approvals to successfully complete clinical studies for a COVID-19 vaccine in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company's operations may not be available or may not be available on terms that are commercially favorable to the Company, the risk that the Company's drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
這些陳述涉及重大風險、不確定因素和假設，包括該公司有能力：提供充足的資金並獲得必要的監管批准，以便及時成功完成新冠肺炎疫苗的臨牀研究並實施其開發計劃。其他風險包括：公司成功地將其藥物配方商業化的能力；可能無法獲得或可能無法以對公司有利的條款獲得足夠資本為公司的運營提供資金的風險；公司的藥物配方可能對其臨牀研究中測試的疾病無效的風險；公司未能遵守與第三方的許可協議條款從而失去在其業務中使用關鍵知識產權的權利的風險；公司保護其知識產權的能力；時間和時間；以及以及公共衞生危機的影響，如新冠肺炎。其中許多將決定實際結果的因素超出了公司的控制或預測能力。
Readers should not unduly rely on these forward-looking statements which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate as such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.
讀者不應過度依賴這些前瞻性陳述，因為它們不能保證未來的業績。不能保證前瞻性表述將被證明是準確的，因為此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，這些因素可能導致實際結果或未來事件與前瞻性表述大不相同。
Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
儘管新聞稿中包含的前瞻性陳述是基於管理層目前認為合理的假設，但公司不能向潛在投資者保證實際結果、業績或成就將與這些前瞻性陳述一致。
All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.
所有前瞻性陳述都是自本新聞稿發佈之日起作出的，可能會發生變化。除法律另有規定外，本公司不承擔更新此類聲明的義務。
For More Information:
有關更多信息，請訪問：
1.866.THE.LASE (843.5273)
416.699.LASE (5273)
1.866.THE.LASE(843.5273)
416.699.LASE(5273)
Kristina Hachey, CPA
Chief Financial Officer
khachey@theralase.com
416.699.LASE (5273) x 224
克里斯蒂娜·哈奇，註冊會計師
首席財務官
郵箱：khaceh@theralase.com
416.699.LASE(5273)x 224